Among the immunoregulatory factors, tumor necrosis factor-α (TNFα), a proinflammatory cytokine, is increased in the mucosa of IBD patients [5] and has been shown to play a central role in the pathogenesis of the disease while anti-TNFα therapy has been shown to be beneficial in the treatment of IBD [6, 7]. Here, TNF is linked to inflammatory bowel disease.